Entera Bio (NASDAQ:ENTX) Trading Up 5.2% – What’s Next?

Entera Bio Ltd. (NASDAQ:ENTX)’s stock price rose 5.2% during trading on Wednesday . The company traded as high as $3.05 and last traded at $3.01. 434,847 shares changed hands during mid-day trading, a decline of 59% from the average session volume of 1,054,112 shares. The stock had previously closed at $2.86.

Analyst Ratings Changes

Several research firms have commented on ENTX. HC Wainwright reissued a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a research note on Friday, July 17th. Finally, Wall Street Zen raised Entera Bio to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.00.

Entera Bio Stock Performance

The stock has a market cap of $514.02 million, a price-to-earnings ratio of -8.42 and a beta of 1.38. The stock’s 50-day simple moving average is $2.71 and its two-hundred day simple moving average is $1.78.

Entera Bio (NASDAQ:ENTX) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06).

Institutional Inflows and Outflows

An institutional investor recently raised its stake in Entera Bio stock. Renaissance Technologies LLC raised its stake in Entera Bio Ltd. (NASDAQ:ENTX) by 338.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 473,442 shares of the company’s stock after purchasing an additional 365,441 shares during the period. Renaissance Technologies LLC owned approximately 0.96% of Entera Bio worth $526,000 as of its most recent SEC filing. 14.11% of the stock is currently owned by institutional investors and hedge funds.

About Entera Bio

Entera Bio Ltd. is a biotechnology company developing orally administered therapies based on large-molecule drugs, including proteins and peptides that are traditionally delivered by injection. The company’s proprietary delivery technology is designed to help these molecules pass through the gastrointestinal tract and reach the bloodstream, with the goal of improving convenience and patient adherence.

Entera Bio’s lead programs have focused on bone and mineral disorders. Its pipeline has included EB613, an oral formulation of parathyroid hormone (PTH 1-34, or teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral PTH product candidate intended for hypoparathyroidism.